Journal: Frontiers in Molecular Neuroscience

Article Title: Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients

doi: 10.3389/fnmol.2019.00335

Figure Lengend Snippet: Plasma BDNF levels according to sex and diagnostic group. BDNF levels in plasma (50 ul) were determined by ELISA. (A) BDNF levels did not differ by sex among subjects included in our study as per Student’s t test, unpaired; two-tailed. (B) No significant differences were detected according to diagnostic group between premanifest (PM), manifest HD (HD), and normal controls (NC) as per One-way ANOVA. Data is shown as individual BDNF levels ± SD.

Article Snippet: A 96-well microtiter plate was incubated overnight at 4°C with a monoclonal mouse anti-human BDNF (100 ul; clone 35928; Calbiochem, San Diego, CA, United States), diluted to 1 μg/ml in filter-sterilized PBS, pH 7.4.

Techniques: Clinical Proteomics, Diagnostic Assay, Enzyme-linked Immunosorbent Assay, Two Tailed Test

Journal: Frontiers in Molecular Neuroscience

Article Title: Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients

doi: 10.3389/fnmol.2019.00335

Figure Lengend Snippet: Correlations between plasma BDNF levels and clinical data in HD patients and control subjects.

Article Snippet: A 96-well microtiter plate was incubated overnight at 4°C with a monoclonal mouse anti-human BDNF (100 ul; clone 35928; Calbiochem, San Diego, CA, United States), diluted to 1 μg/ml in filter-sterilized PBS, pH 7.4.

Techniques: Clinical Proteomics, Control

Journal: Frontiers in Molecular Neuroscience

Article Title: Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients

doi: 10.3389/fnmol.2019.00335

Figure Lengend Snippet: Salivary BDNF levels according to sex and diagnostic group. BDNF levels in saliva (50 ul) were determined by ELISA. (A) No significant differences in BDNF were observed by sex (Student’s t test, unpaired; two-tailed). (B) BDNF levels are lower in premanifest (PM) and manifest HD (HD) cases when compared to normal controls (NC). ∗ p < 0.05; ∗∗ p < 0.01 in comparison to NC group as per One-way ANOVA. (C) BDNF levels are significantly lower in subjects who are >10 years from their predicted age of onset compared to those who are <10 years from predicted onset. ∗ p = 0.05. Predicted age to onset was calculated using the Langbehn formula . Data is shown as individual BDNF levels ± SD.

Article Snippet: A 96-well microtiter plate was incubated overnight at 4°C with a monoclonal mouse anti-human BDNF (100 ul; clone 35928; Calbiochem, San Diego, CA, United States), diluted to 1 μg/ml in filter-sterilized PBS, pH 7.4.

Techniques: Diagnostic Assay, Enzyme-linked Immunosorbent Assay, Two Tailed Test, Comparison

Journal: Frontiers in Molecular Neuroscience

Article Title: Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients

doi: 10.3389/fnmol.2019.00335

Figure Lengend Snippet: Correlations between salivary BDNF levels and clinical data.

Article Snippet: A 96-well microtiter plate was incubated overnight at 4°C with a monoclonal mouse anti-human BDNF (100 ul; clone 35928; Calbiochem, San Diego, CA, United States), diluted to 1 μg/ml in filter-sterilized PBS, pH 7.4.

Techniques:

Journal: Frontiers in Molecular Neuroscience

Article Title: Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients

doi: 10.3389/fnmol.2019.00335

Figure Lengend Snippet: Methylation sites in the BDNF promoter IV region. (A) Schematic representation of human BDNF gene indicating alternative promoters. CpG sites analyzed are detailed in enlarged box. Position is in relation to transcription start site. (B) Detailed sequence of BDNF promoter IV. Underlined text in yellow boxes indicate regions analyzed with each probe by pyrosequencing. Genomic position is based on chromone build GRCh37.p13 primary assembly.

Article Snippet: A 96-well microtiter plate was incubated overnight at 4°C with a monoclonal mouse anti-human BDNF (100 ul; clone 35928; Calbiochem, San Diego, CA, United States), diluted to 1 μg/ml in filter-sterilized PBS, pH 7.4.

Techniques: Methylation, Sequencing

Journal: Frontiers in Molecular Neuroscience

Article Title: Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients

doi: 10.3389/fnmol.2019.00335

Figure Lengend Snippet: DNA methylation status at selected CpG sites from BDNF promoter IV.

Article Snippet: A 96-well microtiter plate was incubated overnight at 4°C with a monoclonal mouse anti-human BDNF (100 ul; clone 35928; Calbiochem, San Diego, CA, United States), diluted to 1 μg/ml in filter-sterilized PBS, pH 7.4.

Techniques: DNA Methylation Assay

Journal: Frontiers in Molecular Neuroscience

Article Title: Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients

doi: 10.3389/fnmol.2019.00335

Figure Lengend Snippet: DNA methylation levels of BDNF promoter IV in blood. Methylation was quantified by pyrosequencing and expressed as mean percent methylation representing the averaged value of cases (HD Gene+) or control subjects (NC) for each of individual CpG. Data represents mean value ± SEM. ∗ p < 0.05 as per two-tailed Student’s t -test.

Article Snippet: A 96-well microtiter plate was incubated overnight at 4°C with a monoclonal mouse anti-human BDNF (100 ul; clone 35928; Calbiochem, San Diego, CA, United States), diluted to 1 μg/ml in filter-sterilized PBS, pH 7.4.

Techniques: DNA Methylation Assay, Methylation, Control, Two Tailed Test

Journal: Frontiers in Molecular Neuroscience

Article Title: Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients

doi: 10.3389/fnmol.2019.00335

Figure Lengend Snippet: Correlations between BDNF promoter IV methylation and clinical measures in HD patients.

Article Snippet: A 96-well microtiter plate was incubated overnight at 4°C with a monoclonal mouse anti-human BDNF (100 ul; clone 35928; Calbiochem, San Diego, CA, United States), diluted to 1 μg/ml in filter-sterilized PBS, pH 7.4.

Techniques: Methylation

Journal:

Article Title: Brain-derived Neurotrophic Factor in Human Saliva: ELISA Optimization and Biological Correlates

doi: 10.1080/15321819.2011.538625

Figure Lengend Snippet: Salivary BDNF Concentrations from ELISA

Article Snippet: A 96-well microtiter plate (Nunc Maxisorp; VWR, West Chester, PA) was incubated overnight at 4°C with 100 μl of monoclonal mouse anti-human BDNF (clone 35928.11; Calbiochem, San Diego, CA), diluted to 1 μg/ml in filter-sterilized PBS, pH 7.4.

Techniques:

Journal:

Article Title: Brain-derived Neurotrophic Factor in Human Saliva: ELISA Optimization and Biological Correlates

doi: 10.1080/15321819.2011.538625

Figure Lengend Snippet: Biological Correlates of Salivary BDNF

Article Snippet: A 96-well microtiter plate (Nunc Maxisorp; VWR, West Chester, PA) was incubated overnight at 4°C with 100 μl of monoclonal mouse anti-human BDNF (clone 35928.11; Calbiochem, San Diego, CA), diluted to 1 μg/ml in filter-sterilized PBS, pH 7.4.

Techniques: